**Phthalates, Bisphenols, and Childhood Allergic Phenotypes: Findings from Two Birth**

**Cohort Studies**

Thomas Boissiere-O'Neill [a], Nina Lazarevic [b], Anne-Louise Ponsonby [c], Peter D. Sly [a], Aimin Chen [d], Tamara L. Blake [a], Jeffrey R. Brook [e], Cassidy Du Berry [f,g,h,i], Louise King [f, h], Piushkumar J. Mandhane [k], Theo J. Moraes [l], Elinor Simons [m], Padmaja Subbarao [e,l,n], Dwan Vilcins [a] , on behalf of BIS* and CHILD investigator groups**

[a] The University of Queensland, Child Health Research Centre, The Children's Health and Environment Program QLD, 4101, Australia.
[b] National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT 2601, Australia
[c] Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC 3010, Australia
[d] Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States
[e] Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
[f] Department of Respiratory and Sleep Medicine, Royal Children's Hospital, Parkville, Victoria, Australia
[g] Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia
[h] Respiratory Group Murdoch Children's Research Institute, Parkville, Victoria, Australia
[i] Respiratory Research@Alfred, Monash University, Melbourne, Victoria, Australia
[k] Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
[l] Department of Pediatrics & Translational Medicine, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
[m] Department of Pediatrics and Child Health, Children's Hospital Research Institute of Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada
[n] Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, Canada

* BIS investigator group: Peter Vuillermin, Anne-Louise Ponsonby, Mimi L.K. Tang, Fiona Collier, Peter D. Sly, Leonard Harrison, Richard Saffery, Sarath Ranganathan, David Burgner, Toby Mansell and Martin O'Hely.
** CHILD investigator group: Padmaja Subbarao, Elinor Simons, Theo J. Moraes, Stuart E. Turvey, Piushkumar J. Mandhane and Meghan B. Azad.

**Correspondence**: Thomas Boissiere-O'Neill, email: t.boissiereoneill@uq.edu.au; ORCID-ID: 0000-0002-7327-3961

**Keywords**: Phthalates, Bisphenols, Pregnancy, Childhood, Allergies, Atopy, Lung function

**Word count (full text):** 3,943

**Word count (abstract):** 245/250

**References:** 48

**Tables:** 4

**Figures:** 4

## ABSTRACT

**Background**

Phthalates and bisphenols may disrupt early immune development, but their impact on allergies and lung function remains uncertain. We investigated associations between prenatal and postnatal exposure to these chemicals, allergies, and lung function in preschool children, focusing on atopic and non-atopic phenotypes.

**Methods**

We used data from the Barwon Infant Study (BIS) and the Canadian Healthy Infant Longitudinal Development Study (CHILD). Urinary metabolites were measured at 36 weeks gestation (BIS) and from three to 36 months postnatally (CHILD). Atopy was assessed via skin prick tests at 4-5 years. Oral food challenge was assessed at one year (BIS). Outcomes included asthma, wheeze, eczema, and rhinitis at 4-5 years. Phenotypes were defined by atopic and outcome status. Lung function at 4-5 years was assessed using multiple-breath washout and oscillometry. We used generalised linear models for single compounds, and quantile G-computation and Bayesian kernel machine regression for exposure mixtures.

**Results**

Exposure mixtures showed a positive association with asthma. Postnatal phthalate mixtures were associated with higher airway resistance and lower reactance. Prenatal exposure mixtures (odds ratio [OR] = 2.24; 95% confidence interval [CI]: 1.03-4.85), as well as postnatal diethyl (OR = 1.50; 95% CI: 1.10-2.04), dibutyl (OR = 1.71; 95% CI: 1.10-2.68) and butyl-benzyl (OR = 1.33; 95% CI: 1.01-1.77) phthalates, were associated with non-atopic asthma. Conversely, prenatal mixtures showed inverse associations with eczema and food allergy.

**Conclusion**

Phthalates may predispose pre-school children to non-atopic asthma but not atopic outcomes. Future studies are needed to confirm these associations.

**HIGHLIGHTS**

- Pre- and postnatal phthalates were associated with non-atopic asthma in children.

- Phthalates and bisphenols were not associated with atopic outcomes.

- Postnatal phthalates were associated with reduced lung function in children.

## 1. INTRODUCTION

Childhood asthma and allergic diseases are highly heterogeneous, comprising different phenotypes likely driven by distinct underlying aetiologies (1, 2). For instance, childhood eczema can be categorised as atopic dermatitis and non-atopic dermatitis, with the latter estimated to have a prevalence of 30% in Australia (2). While the attributable proportion of atopy on these outcomes does not generally exceed 50%, atopic phenotypes generally have different risk factors and clinical presentations compared to non-atopic phenotypes (3). Among the environmental factors potentially contributing to asthma and allergic diseases, early-life exposure to plastic chemicals, such as phthalates and bisphenols, has emerged as a possible cause (4).

Phthalates and bisphenols are among the most common endocrine-disrupting chemicals, with reports indicating that nearly the entire population of developed countries are exposed (5). These chemicals are commonly found in food packaging, personal care products, thermal paper, and resins. In recent years, many studies have shown adverse health outcomes associated with phthalates and bisphenols (5). While there is no evidence of causality, many studies have reported associations between phthalates and bisphenols and adverse health outcomes  (4). However, whether these chemicals contribute to asthma and allergic diseases in children remains uncertain.

Several studies have reported an association between pre- and postnatal exposure to phthalates and bisphenols and asthma and allergic diseases (6-8). However, very few have assessed if they are differentially associated with childhood atopic or non-atopic phenotypes. One study reported that specific phthalates were associated with almost a twofold increase in the risk of eczema in atopic boys up to five years old but not in non-atopic boys (9). Furthermore, two cross-sectional studies reported that serum immunoglobulin E (IgE) mediated the relationship between certain phthalates and bisphenols with allergic outcomes (10, 11), suggesting plastic chemicals orient the immune system towards an atopic T helper (Th) 2 phenotype.

While extensive work has been conducted on plastic chemicals and childhood lung function, most studies have relied on forced breathing manoeuvres such as spirometry, often unsuitable for preschool children (12). Modern tidal-based breathing techniques, such as multiple breath washout or oscillometry, have increased feasibility in this age group and are more sensitive in detecting early peripheral airway changes (13).

Using two birth cohort studies from Australia and Canada, this study aimed to assess the association between prenatal and postnatal exposure to phthalates, bisphenols, and allergic diseases in preschool children, focusing on differences between atopic and non-atopic phenotypes. We also aimed to determine whether the associations with lung function differ between atopic and non-atopic phenotypes.

## 2. METHODS

### 2.1. Study population

Two birth cohorts were used in this study, and detailed descriptions of inclusion and exclusion criteria have been previously published (14, 15). The Barwon Infant Study (BIS) is a population-based longitudinal cohort study with 1,074 mother-infant pairs recruited from the Barwon region in Victoria, Australia (14). Pregnant women at up to 32 weeks' gestation were recruited if they were above 18 years, while children born <32 weeks' gestation were excluded from the study. Ethics approval was granted by the Barwon Health Human Research and Ethics (Study ID 10/24), and families provided informed consent (14). The Canadian Healthy Infant Longitudinal Development (CHILD) study included 3,542 infants born after 35 weeks' gestation, with pregnant mothers recruited during the 2nd or 3rd trimester in four Canadian communities (Vancouver, Edmonton, Manitoba, Toronto). The Human Research Ethics Boards at the Hospital for Sick Children, McMaster University, and the Universities of British Columbia Manitoba, Alberta approved the study, and families provided informed consent (15).

### 2.2. Exposure

#### 2.2.1. BIS

At 36 weeks of gestation, 842 mothers provided a spot-urine sample in glass or polypropylene vials using a standardised protocol (14). Samples were divided into aliquots, stored at -80°C, and shipped to the Queensland Alliance for Environmental Health Science (QAEHS) for instrumental analysis (16, 17). Phthalate and bisphenol metabolites were subsequently corrected for batch effect (18), time of day at urine collection and specific gravity (16). Metabolites included were mono-methyl phthalate (MMP), mono-ethyl phthalate (MEP), mono-isobutyl phthalate (MiBP), mono-n-butyl phthalate (MnBP), mono-benzyl phthalate (MBzP), mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono(5-carboxy-2-ethylpentyl) phthalate (MECPP), mono(3-carboxpropyl) phthalate (MCPP), bisphenol A (BPA), bisphenol S (BPS) and bisphenol F (BPF). For phthalates, values below the limit of detection (LOD) were imputed using LOD/√2 (19). Due to the higher proportion of values below LOD for bisphenols, we imputed values

145  below LOD using multiple imputations with five datasets, each with a left-censored log-normal

146  distribution (17).

### 2.2.2. CHILD

At three, 12, or 36 months of age, 1,578 children provided at least one urine sample (20). Non-toilet-

trained children had their urine collected using plastic film and cotton pads, which were subsequently

squeezed to extract the urine. Samples were stored in cryovials at -80°C and shipped to AXYS

Analytical Services Inc. Phthalates were analysed in urine using the Kato method, as previously

described (20, 21). Analytes were corrected for specific gravity with the Levine-Fahey equation (16).

Metabolites included were MMP, MEP, MiBP, MnBP, MBzP, MEHP, MEOHP, MEHHP, and MCPP.

Values below LOD were imputed with a log-normal distribution using robust regression on order

statistics (20). Children with only one measurement were excluded (n=503) to mitigate measurement

error. For each phthalate, the per-child average of the 3-, 12- and 36-month measurements was

used as the primary exposure variable in this cohort.

### 2.2.3. Daily intake estimation

Phthalate diester estimated daily intake was calculated to standardise metabolites for body weight,

considering urinary fractional excretion, molecular-weight ratio, average daily urinary output and

weight at sampling (16, 22). Urinary MMP was used to estimate the daily intake of dimethyl phthalate

(DMP), MEP for diethyl phthalate (DEP), MnBP for di-n-butyl phthalate (DnBP), MiBP for di-isobutyl

phthalate (DiBP), MBzP for benzyl butyl phthalate (BBzP), and MEHP, MEHHP, MEOHP, and

MECPP for di(2-ethylhexyl) phthalate (DEHP). DiBP and DnBP were summed to derive the total

dibutyl phthalate exposure (DBP). Since MCPP is a non-specific metabolite of high-molecular-weight

phthalates, we did not calculate its daily intake.

### 2.3.  Outcomes

Detailed definitions and collection methods are provided in Supplemental Methods. Children without

any outcomes measured in BIS (n = 9) and CHILD (n = 82) were excluded. In BIS, all outcomes

were assessed at age four years (except food allergy at age one year), whereas in CHILD, we used

those evaluated during the five-year review. Atopic status was determined using a single skin prick

test, based on a wheal size of at least 3 mm greater than the negative control for any of the tested

allergens, in the presence of a positive control ≥ 3 mm and a negative control ≤ 3 mm (23).

In BIS, data on asthma, eczema, and rhinitis were collected through caregiver-reported

questionnaires, whereas in the CHILD study, we used outcomes clinically assessed by subspecialist

paediatricians. Wheeze was recorded in both cohorts based on caregiver-reported outcomes.

Outcome phenotypes were categorised into four mutually exclusive groups based on the presence

or absence of atopy: (i) 'Outcome with atopy,' (ii) 'Outcome without atopy,' (iii) 'Atopy without

outcome,' and (iv) 'No atopy, no outcome (reference)'. Food allergy in BIS was assessed during the

one-year review using a hospital-based open food challenge (23). Challenge-proven food allergy

was not available in CHILD.

Functional residual capacity and lung clearance index were measured using nitrogen ($N_2$)-multiple

breath washout test to evaluate lung gas mixing efficiency. Airway obstruction and compliance were

assessed in BIS using the intrabreath technique (10Hz waveform) with resistance (R) and reactance

(X) at end-inspiration (eI) and end-expiration (eE) recorded (24). The volume dependence of

resistance ($\Delta R = ReE − ReI$) and reactance ($\Delta X = XeE − XeI$) was calculated from these measures.

In CHILD, intrabreath measures were unavailable; instead, spectral (5-37Hz waveform) oscillometry

data were used, measuring resistance and reactance at 8Hz and 19Hz and the area of reactance

(AX) (15).

**2.4.   Sociodemographic and risk factors**

We selected a wide range of variables, identified through a Directed Acyclic Graph (Figure S1),

informed by expert knowledge and previous studies (4, 6). Definitions and cohort availability of each

covariate are shown in Table S1. Sociodemographic factors included maternal age at conception,

child's ethnicity, marital status, remoteness area, caregiver education, and household income. The

Socio-Economic Indexes for Areas (SEIFA) Index of Relative Socioeconomic Disadvantage, a

composite measure of area-based socioeconomic status, was also included as tertiles in BIS (25).

Perinatal and birth characteristics comprised birth year and season of birth, birthweight, sex, and

breastfeeding duration. Family and environmental factors included family history of asthma, tobacco

smoke exposure during pregnancy, smoking inside the house during childhood, home renovation,

household size, and pet ownership. In BIS, maternal diet during pregnancy was assessed using a

food frequency questionnaire and principal component analysis (16, 26). This analysis identified

three dietary patterns: (i) a modern healthy diet, (ii) a western unhealthy diet, and (iii) a traditional

Anglo-Saxon diet. Factor loadings were categorised into tertiles (low, medium, high), reflecting diet

adherence. We also incorporated a Chemical burden score in BIS, based on the frequency of

household product use during pregnancy, as previously developed by the Avon Longitudinal Study

of Parents And Children (ALSPAC) cohort (16, 27).

## 2.5.   Statistical analysis

Population characteristics and exposure concentrations were summarised using descriptive

statistics. Since exposure variables followed a log-normal distribution, we applied log2

transformation. All lung function measures were scaled to a mean of 0 and a standard deviation of

1 to enable direct comparison between models. We conducted a complete case analysis. Models

involving bisphenols were pooled using Rubin's rule to account for the multiple imputation of values

below LOD. Given the differences in exposure measurements, and outcome assessments between

BIS and CHILD, estimates were not pooled between cohorts.

### 2.5.1.  Single compound analysis

The shape of the relationship between exposures and outcomes was determined through

generalised linear models with and without restricted cubic splines with three knots (10th, 50th, and

90th percentiles), chosen using Akaike Information Criteria (28). Differences in means with 95%

confidence intervals (CI) were estimated with linear regression for continuous outcomes. Odds ratios

(OR) and 95% CI were estimated with logistic regression for binary outcomes. We followed a

systematic approach to build the multivariable models (29). Initially, we screened all variables

associated with exposures and outcomes. We then selected variables that changed the estimate in

the exposure-outcome relationships by at least 10% in bivariable models to construct minimally

adjusted models (29). Variables associated with outcomes that did not substantially change

exposure-outcome associations were then added to construct fully adjusted models. We estimated

associations between exposures and outcome phenotypes with multinomial logistic regression,

estimating odds ratios (OR) with 95% CI, using 'No atopy no outcome'' as the reference category.

Given the common exposure to grass and house dust mites (HDM) and the relative independence

of sensitisation to these allergens from factors like pet ownership (30), we investigated whether

exposures were associated with HDM/grass sensitisation. Children were categorised into four

mutually exclusive groups: 'No grass-No HDM' (reference), 'HDM-exclusive', 'Grass-exclusive', and

'Grass-HDM'. The association between exposures and HDM/grass sensitisation was also evaluated

using multinomial regression.

### *2.5.2.  Mixture analysis*

We employed Bayesian kernel machine regression (BKMR) to investigate the associations between

exposure mixtures and overall outcomes (31). BKMR is a flexible, non-parametric approach that

estimates the joint effects of environmental mixtures while accounting for nonlinear relationships, co-

exposure interactions, and directional heterogeneity. This method employs a designated kernel

function to estimate exposure effects by measuring distances between individuals in the exposure

space. For BKMR, all exposures were centred to a mean of 0 and a standard deviation of 1 to

facilitate model convergence. Prior distributions for the smoothing parameter (r) were identified using

frequentist kernel machine regression, and uninformative priors were used for the remaining

parameters in the final model (31). We adjusted the Metropolis-Hastings parameters ($r_{jump}$, $\lambda_{jump}$) to

achieve acceptance rates of 20-40%. Markov Chain Monte-Carlo sampler was run for 10,000

iterations, and the first 4,000 were disregarded after assessing convergence. Since BKMR does not

allow for multinomial outcomes and the sample sizes were lower for outcome phenotypes, we

employed multinomial quantile G-computation to evaluate associations between exposure mixtures

and outcome phenotypes. This method estimates the joint effects of the mixture by fitting a marginal

structural model with discretised exposures, allowing for the effect estimation of the simultaneous

increase of all exposures by one quantile (32). We estimated odds ratio (OR) with 95% CI associated

with one quartile increase in each plasticiser within the mixture.

## 3. RESULTS

### 3.1. Sample characteristics

A total of 838 children from BIS and 993 from CHILD had data on exposures and outcomes.

Exposure distributions and detection rates are shown in Table S2-S3. Urinary metabolite

concentrations were higher in BIS than in CHILD. However, relative to body weight, children in

CHILD had higher estimated daily intakes than pregnant women in BIS, except for DEP. BIS had a

lower proportion of university-educated caregivers, a lower rate of tobacco smoke exposure during

pregnancy, smaller households, and a higher proportion of Caucasian/White children compared to

CHILD (Table 1-2). Overall, allergic outcomes were more prevalent in BIS compared to CHILD. In

BIS, food allergy at one year had the lowest prevalence (7.7%), while wheezing during the first four

years was the most common outcome (67.2%). In CHILD, current asthma at five years was the least

prevalent outcome (6.9%), while current eczema had the highest prevalence (17.9%).

Table 1. Descriptive characteristics of the Barwon Infant Study

| | Full cohort (N = 1,074) | | Study sample (N = 838) | |
|---|---|---|---|---|
| | N | N (%) or mean [SD] | N | N (%) or mean [SD] |
| **Perinatal and birth characteristics** | | | | |
| Year of birth | 1,074 | | 838 | |
| 2010-2011 | | 417 (38.8) | | 312 (37.2) |
| 2012 | | 392 (36.5) | | 303 (36.2) |
| 2013 | | 265 (24.7) | | 223 (26.6) |
| Season of birth | 1,074 | | 838 | |
| Autumn | | 275 (25.6) | | 209 (24.9) |
| Spring | | 216 (20.1) | | 176 (21.0) |
| Summer | | 274 (25.5) | | 196 (23.4) |
| Winter | | 309 (28.8) | | 257 (30.7) |
| Male | 1,074 | 555 (51.7) | 838 | 438 (52.3) |
| Breastfeeding duration (weeks) | 624 | 22.3 [17.0] | 500 | 23.9 [17.1] |
| Birthweight (kg) | 1,074 | 3.5 [0.5] | 838 | 3.6 [0.5] |
| **Sociodemographic factors** | | | | |
| Maternal age at conception | 1,071 | 31.9 [4.8] | 838 | 32.4 [4.5] |
| Lone parenthood | 1,068 | 42 (3.9) | 835 | 24 (2.9) |
| Caucasian/white | 1,060 | 799 (75.4) | 829 | 634 (76.5) |
| Caregiver university educated | 1,070 | 537 (50.2) | 838 | 449 (53.6) |
| SEIFA tertiles | 1,071 | | 837 | |
| 1 (Most disadvantaged) | | 272 (25.4) | | 193 (23.1) |
| 2 | | 206 (19.2) | | 158 (18.9) |
| 3 (Least disadvantaged) | | 593 (55.4) | | 486 (58.1) |
| Household income | 1,041 | | 816 | |
| < 75,000 AUD | | 311 (29.9) | | 221 (27.1) |
| 75,000 – 99,999 AUD | | 266 (25.6) | | 211 (25.9) |
| 100,000 – 149,999 AUD | | 343 (32.9) | | 286 (35.0) |
| ≥ 150,000 AUD | | 121 (11.6) | | 98 (12.0) |
| **Family and Environmental Factors** | | | | |
| Family history of asthma | 1,069 | 542 (50.7) | 837 | 415 (49.6) |
| Tobacco smoke exposure during pregnancy | 1,069 | 169 (15.9) | 832 | 102 (12.3) |
| Smoking inside the house (4 years) | 789 | 1 (0.1) | 689 | 0 (0.0) |
| House renovation during pregnancy | 970 | 625 (64.4) | 773 | 499 (64.6) |
| Household size | 1,067 | | 830 | |
| 2 | | 428 (40.1) | | 334 (40.0) |
| 3 | | 369 (34.6) | | 300 (35.9) |
| ≥ 4 | | 270 (25.3) | | 201 (24.1) |
| Pet ownership during pregnancy | 1,068 | 788 (73.8) | 831 | 615 (73.6) |
| Chemical burden score | 554 | 9.4 [5.2] | 552 | 9.4 [5.2] |
| **Lung function (4 years)** | | | | |
| Lung clearance index (turnovers) | 222 | 6.2 [0.4] | 205 | 6.2 [0.4] |
| Functional residual capacity (L) | 222 | 0.6 [0.1] | 205 | 0.6 [0.1] |
| Resistance at end-expiration ($cmH_2O.s/L$) | 433 | 8.8 [2.2] | 393 | 8.7 [2.2] |
| Resistance at end-inspiration ($cmH_2O.s/L$) | 433 | 7.9 [1.8] | 393 | 7.8 [1.8] |
| Reactance at end-expiration ($cmH_2O.s/L$) | 433 | -1.5 [1.6] | 393 | -1.4 [1.6] |
| Reactance at end-expiration ($cmH_2O.s/L$) | 433 | -1.7 [1.0] | 393 | -1.7 [1.0] |
| Volume dependence of resistance ($cmH_2O.s/L$) | 433 | 0.9 [1.3] | 393 | 0.9 [1.3] |
| Volume dependence of reactance ($cmH_2O.s/L$) | 433 | 0.2 [1.3] | 393 | 0.2 [1.3] |
| **Child outcomes** | | | | |
| Current asthma (4 years) | 893 | 144 (16.1) | 761 | 117 (15.4) |
| Ever wheeze (4 years) | 817 | 571 (69.9) | 693 | 466 (67.2) |
| Ever eczema (4 years) | 749 | 264 (35.2) | 658 | 227 (34.5) |
| Current rhinitis (4 years) | 797 | 99 (12.4) | 695 | 87 (12.5) |
| Food allergy (1 year) | 804 | 58 (7.2) | 689 | 53 (7.7) |
| Atopy (4 years) | 513 | 144 (28.1) | 467 | 134 (28.7) |

273 Abbreviations: SEIFA: Socio-Economic Indexes for Areas

Table 2. Descriptive characteristics of the Canadian Healthy Infant Longitudinal Development

Study

| | Full cohort (N = 3,263) | | Study sample (N = 993) | |
|---|---|---|---|---|
| | N | N (%) or mean [SD] | N | N (%) or mean [SD] |
| **Centre of recruitment** | 3,263 | | 993 | |
| Edmonton | | 769 (23.6) | | 180 (18.1) |
| Toronto | | 770 (23.6) | | 172 (17.3) |
| Vancouver | | 730 (22.4) | | 296 (29.8) |
| Winnipeg | | 994 (30.5) | | 345 (34.7) |
| **Perinatal and Birth Characteristics** | | | | |
| Year of birth | 3,215 | | 993 | |
| 2009-2010 | | 902 (28.1) | | 461 (46.4) |
| 2011 | | 1,747 (54.3) | | 532 (53.6) |
| 2012 | | 566 (17.6) | | 0 (0.0) |
| Season of birth | 3,263 | | 993 | |
| Autumn | | 754 (23.1) | | 201 (20.2) |
| Spring | | 889 (27.2) | | 286 (28.8) |
| Summer | | 830 (25.4) | | 310 (31.2) |
| Winter | | 790 (24.2) | | 196 (19.7) |
| Male | 3,263 | 1,717 (52.6) | 993 | 550 (55.4) |
| Birthweight (kg) | 3,194 | 3.4 [0.5] | 964 | 3.5 [0.5] |
| Breastfeeding duration (weeks) | 3,157 | 41.6 [27.2] | 993 | 44.3 [26.6] |
| **Sociodemographic factors** | | | | |
| Maternal age at conception | 3,136 | 32.2 (4.7) | 971 | 32.3 [4.5] |
| Lone parenthood | 3,156 | 188 (6.0) | 975 | 46 (4.7) |
| Ethnicity | 3,263 | | 993 | |
| Caucasian/white | | 2,247 (68.9) | | 704 (70.9) |
| Multiracial | | 493 (15.1) | | 153 (15.4) |
| Other | | 523 (16.0) | | 136 (13.7) |
| Caregiver university educated | 3,263 | | 993 | 818 (82.4) |
| Household income | 2,837 | | 879 | |
| < 80,000 CAD | | 1,214 (42.8) | | 280 (31.9) |
| 80,000-149,999 CAD | | 923 (32.5) | | 388 (44.1) |
| ≥ 150,000 CAD | | 700 (24.7) | | 211 (24.0) |
| **Family and Environmental Factors** | | | | |
| Family history of asthma | 3,205 | 660 (20.6) | 988 | 218 (22.1) |
| Tobacco smoke exposure during pregnancy | 3,163 | 606 (19.2) | 976 | 155 (15.9) |
| Smoking inside the house (5 years) | 2,121 | 13 (0.6) | 792 | 6 (0.8) |
| House renovation (5 years) | 2,992 | 909 (30.4) | 965 | 305 (31.6) |
| Household size (≥ 4 vs. <4) | 2,989 | 1,684 (56.3) | 965 | 541 (56.1) |
| Pet ownership (5 years) | 2,302 | 912 (39.6) | 848 | 339 (40.0) |
| **Lung function (5 years)** | | | | |
| Lung clearance index (turnovers) | 205 | 7.3 (1.0) | 54 | 7.3 [0.9] |
| Functional residual capacity (L) | 205 | 0.7 (0.1) | 54 | 0.7 [0.2] |
| Resistance at 8 Hz ($cmH_2O.s/L$) | 500 | 10.8 (2.5) | 154 | 10.9 [2.4] |
| Resistance at 19 Hz ($cmH_2O.s/L$) | 500 | 9.1 (2.3) | 154 | 9.3 [2.2]] |
| Reactance at 8 Hz ($cmH_2O.s/L$) | 500 | -3.6 (1.5) | 154 | -3.4 [1.5] |
| Reactance at 19 Hz ($cmH_2O.s/L$) | 500 | -2.0 (1.4) | 154 | -1.9 [1.4] |
| Area under the reactance ($cmH_2O/L$) | 500 | 56.1 (33.3) | 154 | 53.0 [32.3] |
| **Child outcomes (5 years)** | | | | |
| Current asthma | 2,399 | 165 (6.9) | 889 | 62 (7.0) |
| Current wheeze | 2,302 | 226 (9.8) | 857 | 79 (9.2) |
| Current eczema | 1,998 | 357 (17.9) | 738 | 132 (17.9) |
| Current rhinitis | 2,395 | 188 (7.8) | 901 | 77 (8.5) |
| Atopy | 2,534 | 305 (12.0) | 937 | 123 (13.1) |

### 3.2. Allergic diseases and lung function

#### 3.2.1. Single compounds associations

A twofold increase in prenatal DEHP was associated with increased odds of wheezing in the first four years of life (OR = 1.19; 95% CI: 1.00-1.43). Furthermore, BBzP was inversely associated with atopy (OR = 0.84; 95% CI: 0.71-0.98). No associations were observed for food allergy or other outcomes (Table S4). Similarly, prenatal phthalate and bisphenol levels were not associated with multiple breath washout or intrabreath oscillometry endpoints (Table S5). However, prenatal DEP levels demonstrated an inverted U-shape dose-response relationship with ReE and ReI, while BBzP exhibited a U-shape dose-response relationship with XeE (Figure S2). There were no substantial differences between minimally and fully adjusted models (Table S4-S5).

Low-molecular-weight phthalates during childhood, such as DEP (OR = 1.33; 95% CI: 1.02-1.74) and DBP (OR = 1.67; 95% CI: 1.13-2.50), were associated with asthma at age five (Table S6). DBP levels were also associated with wheezing (OR = 1.67; 95% CI: 1.14-2.44). Childhood exposure to phthalates was not associated with eczema, rhinitis, or atopy. In fully adjusted, but not minimally adjusted models, DBP levels were associated with decreased X8 (Table S7; mean z-score change = -0.25; 95% CI: -0.48; -0.02), X19 (mean z-score change = -0.25; 95% CI: -0.48; -0.01), and increased AX (mean z-score change = 0.24; 95% CI: 0.00; 0.47). Similarly, postnatal BBzP was associated with reduced X8 (mean z-score change = -0.23; 95% CI: -0.41; -0.04), X19 (mean z-score change = -0.20; 95% CI: -0.39; -0.01), and increased AX (mean z-score change = 0.21; 95% CI: 0.03; 0.40). Last, MCPP was associated with increased R8 (mean z-score change = 0.23; 95% CI: 0.00; 0.47).

### 3.2.2. Mixture associations

Using BKMR, the prenatal exposure mixture in BIS was positively associated with asthma, but inversely with food allergy and eczema (Figure S3). However, we observed no significant associations with wheezing, rhinitis, or atopy. Although the associations between the prenatal exposure mixture, ReE and ReI, tended to show inverse U dose-response relationships, there was no clear evidence of an association with lung function (Figure S4). Childhood phthalate mixture in CHILD was associated with an increased risk of asthma and wheezing at age five (Figure S5). Additionally, there was a linear, positive association with R8, R19 and AX, along with an inverse association with X8 and X19 (Figure S6).

## 3.3.  Atopic vs. non-atopic phenotypes

### 3.3.1. Single compound associations

#### 3.3.1.1.  Prenatal exposure (BIS)

A twofold increase in DEHP exposure was associated with higher odds of non-atopic wheeze (OR=1.30; 95% CI: 1.00-1.67; Figure 1). MCPP exposure was associated with increased odds of non-atopic asthma at age four (OR = 1.20; 95% CI: 1.02-1.40). In contrast, BBzP was associated with reduced odds of atopy without eczema (OR = 0.68; 95% CI: 0.53-0.87) or without rhinitis (OR = 0.82; 95% CI: 0.69-0.97). Finally, the odds of atopy without eczema were also decreased with increasing DEHP exposure (OR = 0.61; 95% CI: 0.42-0.89).

There was no evidence, overall, that the associations between prenatal exposure and lung function outcomes differed by atopic status (Figure 2). However, the relationship between prenatal DEP exposure and four-year intrabreath oscillometry measures varied by atopic status (p<0.05 for interaction). Specifically, a decrease in ReE (mean z-score change = -0.19; 95% CI: -0.30; -0.09) and ReI (mean z-score change = -0.20; 95% CI: 0.-30; -0.10) was observed in atopic children, while a decrease in XeE (mean z-score change = -0.08; 95% CI: -0.16; 0.00) and ΔX (mean z-score change = -0.10; 95% CI: -0.19; -0.02) was seen in non-atopic children. DEP exhibited an inverse U-shaped dose-response curve in both atopic and non-atopic groups (Figure S7).

Figure 1. Adjusted odds ratios (and 95% confidence intervals) for outcome phenotypes associated with a twofold increase in prenatal (BIS) phthalates and bisphenols

*N asthma=436; N wheeze=399; N eczema=384; N rhinitis=433.*

*Reference category (A⁻ O⁻: No atopy, no outcome). Empty circles denote estimates for which the 95% confidence interval does not include the null. Models were adjusted for age at outcome assessment, family history of asthma, year and season of birth, child's ethnicity, western diet during pregnancy, SEIFA, household income, and household size.*

*Abbreviations: A⁺ O⁺: Outcome with atopy, A⁻ O⁺: Outcome without atopy, A⁺ O⁺: Atopy without outcome, BBzP: Butyl Benzyl Phthalate; BIS: Barwon Infant Study; BPA: Bisphenol A; BPF: Bisphenol F; BPS: Bisphenol S; DBP: Dibutyl Phthalate; DEHP: Di(2-ethylhexyl) Phthalate; DEP: Diethyl Phthalate; DMP: Dimethyl Phthalate; MCPP: Mono(3-carboxypropyl) Phthalate*

Figure 2. Mean-z-score changes (and 95% confidence intervals) for lung function outcomes associated with a twofold increase in prenatal (BIS) phthalates and bisphenols, stratified by atopic status

*N atopic=43-83 ; N non-atopic=121-198*

*Empty circles denote estimates for which the 95% confidence interval does not include the null. Adjusted for family history of asthma, age at outcome assessment, birthweight, year and season of birth, prenatal alcohol consumption, caregiver education, household income, and household size*

*Abbreviations: BBzP: Butyl Benzyl Phthalate; BIS: Barwon Infant Study; BPA: Bisphenol A; BPF: Bisphenol F; BPS: Bisphenol S; DBP: Dibutyl Phthalate; DEHP: Di(2-ethylhexyl) Phthalate; DEP: Diethyl Phthalate; DMP: Dimethyl Phthalate; FRC: Functional residual capacity, LCI: Lung clearance index; MCPP: Mono(3-carboxypropyl) Phthalate; ReE: Resistance at end-expiration ; ReI: Resistance at end-inspiration ; XeE: Reactance at end-expiration; Xei: Reactance at end- inspiration ; ΔR: Volume dependence of resistance; ΔX: Volume dependence of reactance. pint: interaction p-value*

### 3.3.1.2. Postnatal exposure (CHILD)

Childhood DEP (OR=1.50; 95% CI: 1.10-2.04), DBP (OR = 1.71; 95% CI: 1.10-2.68) and BBzP (OR = 1.33; 95% CI: 1.01-1.77) increased the likelihood of non-atopic asthma at five years of age (Figure 3). Furthermore, DEP (OR = 1.36; 95% CI: 1.02-1.82) and DBP (OR = 1.83; 95% CI: 1.18-2.82) levels were also associated with non-atopic wheeze. MCPP tended to show an inverse association with non-atopic rhinitis (OR = 0.66; 95% CI: 0.42-1.03) and a positive association with atopic rhinitis (OR = 1.91; 95% CI: 0.95-3.86), although the confidence intervals included the null.

Figure 3. Adjusted odds ratios (and 95% confidence intervals) for outcome phenotypes associated with a twofold increase in postnatal (CHILD) phthalates

*$N_{asthma}$=641; $N_{wheeze}$=627; $N_{eczema}$=543; $N_{rhinitis}$=646.*
*Reference category ($A^- O^-$: No atopy, no outcome). Empty circles denote estimates for which the 95% confidence interval does not include the null. Models were adjusted for age at outcome assessment, child's ethnicity, child's sex, pet ownership, family history of asthma, year and season of birth, child's ethnicity, maternal smoke exposure during pregnancy, household income, and household size.*
*Abbreviations: $A^+ O^+$: Outcome with atopy, $A^- O^+$: Outcome without atopy, $A^+ O^+$: Atopy without outcome, BBzP: Butyl Benzyl Phthalate; DBP: Dibutyl Phthalate; DEHP: Di(2-ethylhexyl) Phthalate; DEP: Diethyl Phthalate; MCPP: Mono(3-carboxypropyl) Phthalate*

The association between childhood MCPP and R8 tended to vary by atopic status (Figure 4, p =

0.06 for interaction). Specifically, MCPP was associated with increased R8 (mean z-score change =

0.61; 95%CI: 0.11; 1.11) and increased R19 (mean z-score change = 0.55; 95%CI: 0.03; 1.08) only

in atopic children.

Figure 4. Mean-z-score changes (and 95% confidence intervals) for lung function outcomes
associated with a twofold increase in postnatal (CHILD) phthalates, stratified by atopic status
*N atopic=4-19 ; N non-atopic=26-79.*
*p-values are shown for the multiplicative interaction term between atopy and individual compounds. Empty*
*circles denote estimates for which the 95% confidence interval does not include the null. Adjusted for age at*
*outcome assessment, child's sex, height, ethnicity, pet ownership, family history of asthma, year and season*
*of birth, maternal smoke exposure during pregnancy, household income, and household size*
*Abbreviations: AX: Area of reactance; BBzP: Butyl Benzyl Phthalate; DBP: Dibutyl Phthalate; DEHP: Di(2-*
*ethylhexyl) Phthalate; DEP: Diethyl Phthalate; FRC: Functional residual capacity, LCI: Lung clearance index;*
*MCPP: Mono(3-carboxypropyl) Phthalate; R8: Resistance at 8Hz; R19: Resistance at 19Hz; X8: Reactance at*
*8Hz; R19: Reactance at 19Hz; $p_{int:}$ interaction p-value.*

### 3.3.2. Mixture associations

A one-quartile increase in the prenatal exposure mixture in BIS was associated with 2.2-fold higher odds of developing non-atopic asthma at age four (OR = 2.24; 95% CI: 1.03-4.85; Table 3). No associations were observed between the prenatal exposure mixture and other outcome phenotypes. Although the confidence interval included the null, the same trend was observed between the postnatal exposure mixture in CHILD and non-atopic asthma at age five (OR = 1.57; 95% CI: 0.95–2.60).

Table 3. Adjusted odds ratios (and 95% confidence intervals) for outcome phenotypes associated with a one-quartile increase in pre- and postnatal exposure mixtures.

| | No outcome, No atopy | | Outcome with atopy | | Outcome without atopy | | Atopy without outcome | |
|---|---|---|---|---|---|---|---|---|
| | N | OR (95%CI) | N | OR (95%CI) | N | OR (95%CI) | N | OR (95%CI) |
| **Prenatal exposure (BIS) [a]** | | | | | | | | |
| Current asthma | 278 | *Reference* | 39 | 0.90 (0.45-1.83) | 37 | **2.24 (1.03-4.85)** | 82 | 0.95 (0.53-1.70) |
| Ever wheeze | 110 | *Reference* | 82 | 0.86 (0.45-1.66) | 178 | 0.95 (0.53-1.69) | 29 | 0.80 (0.32-2.00) |
| Ever eczema | 208 | *Reference* | 66 | 0.78 (0.44-1.39) | 68 | 0.85 (0.41-1.75) | 42 | 0.71 (0.32-1.58) |
| Current rhinitis | 288 | *Reference* | 28 | 0.86 (0.37-2.01) | 24 | 1.60 (0.62-4.14) | 93 | 0.87 (0.52-1.46) |
| **Postnatal exposure (CHILD) [b]** | | | | | | | | |
| Current asthma | 529 | *Reference* | 8 | 1.18 (0.32-4.31) | 37 | 1.57 (0.95-2.60) | 67 | 1.22 (0.84-1.79) |
| Current wheeze | 507 | *Reference* | 12 | 1.08 (0.40-2.95) | 41 | 1.56 (0.97-2.52) | 67 | 1.15 (0.79-1.68) |
| Current eczema | 402 | *Reference* | 17 | 1.38 (0.67-2.86) | 77 | 1.06 (0.74-1.50) | 47 | 1.25 (0.80-1.95) |
| Current rhinitis | 536 | *Reference* | 16 | 1.52 (0.65-3.58) | 33 | 0.69 (0.41-1.16) | 61 | 1.10 (0.74-1.62) |

*Models obtained with quantile G-computation*
*[a] Adjusted for age at outcome assessment, family history of asthma, year and season of birth, child's ethnicity, western diet during pregnancy, SEIFA, household income, and household size.*
*[b] Adjusted for centre of recruitment, age at outcome assessment, child's ethnicity, child's sex, pet ownership, family history of asthma, year and season of birth, child's ethnicity, maternal smoke exposure during pregnancy, household income, and household size.*
*Abbreviations: BIS: Barwon Infant Study; CHILD: Canadian Healthy Infant Longitudinal Development Study; CI: Confidence interval; OR: Odds Ratio.*

We found that childhood phthalate mixture was only associated with reduced reactance at 8Hz in atopic children (Table 4; mean z-score change = -0.75; 95% CI: -1.41; -0.09; p = 0.07 for interaction). However, there was no evidence that the association between pre- and postnatal exposure to chemical mixtures and lung function differed by atopic status.

Table 4. Adjusted odds ratios (and 95% confidence intervals) for lung function outcomes associated with one quartile increase in pre- and postnatal exposure mixtures, stratified by atopic status

| | Atopic | | Non-atopic | | p for interaction |
|---|---|---|---|---|---|
| | N | Mean z-score change (95%CI) | N | Mean z-score change (95%CI) | |
| **Prenatal exposure (BIS) [a]** | | | | | |
| FRC | 43 | 0.29 (-0.35;0.92) | 121 | -0.19 (-0.53;0.15) | 0.18 |
| LCI | 43 | -0.08 (-0.87;0.70) | 121 | 0.13 (-0.29;0.55) | 0.64 |
| ReE | 82 | -0.06 (-0.58;0.45) | 198 | 0.06 (-0.23;0.34) | 0.69 |
| ReI | 82 | 0.08 (-0.45;0.62) | 198 | 0.02 (-0.26;0.31) | 0.84 |
| XeE | 82 | -0.11 (-0.64;0.42) | 198 | -0.03 (-0.35;0.29) | 0.80 |
| XeI | 82 | -0.13 (-0.66;0.40) | 198 | -0.11 (-0.39;0.16) | 0.96 |
| ΔR | 82 | -0.22 (-0.71;0.28) | 198 | 0.07 (-0.22;0.36) | 0.33 |
| ΔX | 82 | -0.04 (-0.59;0.52) | 198 | 0.05 (-0.31;0.42) | 0.80 |
| **Postnatal exposure (CHILD) [b]** | | | | | |
| FRC | 4 | - | 26 | - | - |
| LCI | 4 | - | 26 | - | - |
| R8 | 19 | 0.62 (-0.02;1.27) | 76 | 0.16 (-0.15;0.48) | 0.20 |
| R19 | 19 | 0.45 (-0.24;1.14) | 76 | 0.15 (-0.19;0.49) | 0.44 |
| X8 | 19 | -0.75 (-1.41;-0.09) | 76 | -0.07 (-0.39;0.25) | 0.07 |
| X19 | 19 | -0.40 (-1.03;0.23) | 76 | -0.14 (-0.45;0.17) | 0.46 |
| AX | 19 | 0.58 (-0.05;1.21) | 76 | 0.12 (-0.18;0.43) | 0.19 |

*Models obtained with quantile G-computation. p-values are shown for the multiplicative interaction term between the exposure mixture and atopy. Models involving postnatal exposure and multiple breath washout did not converge due to low sample size.*

*[a] Adjusted for age at outcome assessment, height, family history of asthma, year and season of birth, child's ethnicity, western diet during pregnancy, SEIFA, household income, and household size.*

*[b] Adjusted for centre of recruitment, age at outcome assessment, height child's ethnicity, child's sex, pet ownership, family history of asthma, year and season of birth, child's ethnicity, maternal smoke exposure during pregnancy, household income, and household size.*

*Abbreviations: AX: Area of reactance; FRC: Functional residual capacity, LCI: Lung clearance index; R8: Resistance at 8Hz; R19: Resistance at 19Hz; ReE: End-expiration resistance; ReI: End- inspiration resistance; X8: Reactance at 8Hz; R19: Reactance at 19Hz; XeE: End-expiration reactance; XeI: End-inspiration reactance; ΔR: Volume dependence of resistance; ΔX: Volume dependence of reactance.*

### 3.4. Secondary analysis

Prenatal DMP exposure in BIS was associated with reduced odds of sensitisation to both HDM and grass (Table S8; OR = 0.65; 95% CI: 0.49-0.87), and prenatal BBzP was associated with decreased likelihood of sensitisation to grass only (OR = 0.70; 95% CI: 0.52-0.93). In contrast, postnatal MCPP levels were associated with a twofold increase in the odds of sensitisation to both HDM and grass (OR = 2.28; 95% CI: 1.08-4.77).

## 4. DISCUSSION

In this study, exposure to phthalate and bisphenol mixtures during pregnancy was associated with an increased risk of non-atopic asthma by age four. Additionally, exposure to specific phthalates in early childhood was associated with non-atopic asthma at age five. Furthermore, the exposure mixture during childhood was associated with higher airway resistance and lower reactance. However, the exposure mixture during pregnancy was inversely associated with eczema during the first four years of life and with challenge-proven food allergies at one year.

While preclinical studies have suggested that plasticiser exposure promotes a Th2 immune response (4), this study does not support that hypothesis. No association was found between phthalate exposure and atopy in either cohort, as measured by skin prick tests. Furthermore, we found inverse associations between prenatal mixtures and challenge-proven food allergy. In the Kingston Allergy Birth Cohort, higher DEHP exposure was associated with reduced odds of sensitisation in children up to three years old (33). Similarly, previous cross-sectional studies found reduced odds of allergen sensitisation (measured by IgE) in adults but no association in children (34). An exposome-wide association study involving six cohorts also found no associations between plasticisers and caregiver-reported food allergy (35).

Although some studies report an increased risk of food allergy with prenatal phthalate exposure (36-38), differences in outcome assessment methods and exposure levels may explain inconsistencies. Non-monotonic dose-response relationships could lead to varying results across populations (39). Additionally, latent effects of EDCs may account for findings in older children (40), such as an association with food allergy at age nine (36), but not at one year. Overall, human evidence for a relationship between phthalates and IgE-mediated outcomes remains limited. Large-scale, long-term prospective studies are needed to clarify these relationships.

The inverse associations observed between prenatal exposures and allergic outcomes are unlikely to be causal. There is no biological basis to suggest that prenatal phthalates and bisphenols protect

against atopic conditions. Instead, live-birth bias may explain these findings. Phthalate exposure has been associated with early pregnancy loss (41), and if an unmeasured confounder (i.e., prenatal stress, genetic susceptibility, or other environmental chemicals) affects both early pregnancy loss and atopy, conditioning on live birth can lead to overprotective associations in live-born children (42). For instance, applying correction factors from the epidemiologic literature (43), an unmeasured confounder would need to increase the risk of both early pregnancy loss and atopy by 2.66 times to nullify the observed OR of 0.61 for DEHP and atopy without eczema.

Animal models have also suggested plasticisers enhance neutrophilic Th17-mediated inflammation (4). In this study, pre-and postnatal phthalates were associated with non-atopic asthma at four to five years of age, a phenotype typically associated with neutrophilic inflammation, driven by Th1 or Th17 cell activation (44). The underlying mechanism often involves oxidative stress-mediated DNA methylation (44). Despite differences in populations, exposure windows, and outcome assessment methods, we found an association with non-atopic asthma in both cohorts. Furthermore, this finding is consistent with those of the ALSPAC cohort, which found that prenatal household chemicals were associated with an increased risk of wheezing in non-atopic children under seven years of age (45).

In this study, postnatal exposure to low-molecular-weight phthalates was associated with increased airway resistance and decreased reactance. These findings are consistent with a previous cross-sectional study that reported an association between low-molecular-weight phthalates and airway resistance at 5Hz in children aged 10–12 years (46). While this study identified serum periostin (promoter of Th2 immune response) as a mediator of this relationship, suggesting Th2-driven airway inflammation and remodelling, our results did not show substantial differences in estimates between atopic and non-atopic children.

This study has several strengths. It is the first study to investigate the association between prenatal exposure to phthalates and bisphenols and food allergies, using an oral food challenge, the gold standard for diagnosing IgE-mediated food allergies. Our findings regarding food allergy, however, should be replicated with similar outcome assessment methods. We used novel lung function

assessment methods, and focused on atopic and non-atopic phenotypes, providing more nuanced

understanding of potential associations.  Using two distinct cohorts strengthened the robustness and

generalisability of our findings, enabling us to evaluate these associations in different geographic

and methodological settings. Despite differences in sampling techniques, exposure windows, and

outcome measures, this strategy allowed us to assess the consistency of results, rather than relying

on a single cohort study. However, the differences in data collection timing and methods between

BIS and CHILD limited the potential for direct comparisons. Furthermore, relying on a single-spot

urine sample for prenatal analysis may have led to underestimation of associations, particularly given

the short half-lives of these chemicals. Although the prenatal analysis primarily relied on caregiver-

reported outcomes, the questionnaires demonstrated satisfactory sensitivity and specificity (47, 48).

Overall, exposure to phthalates was associated with an increased risk of non-atopic asthma in

children aged four to five years, across two cohorts, despite differences in exposure windows and

outcome assessment methods. However, these chemicals showed inverse or no associations with

other allergic outcomes. Future studies with extensive exposure assessments throughout pregnancy

and childhood and similar outcome assessment methods are needed to clarify further the influence

of phthalate and bisphenol exposure on early immune and respiratory development.

## CRediT authorship contribution statement

**Thomas Boissiere-O'Neill**: Conceptualisation, Methodology, Formal analysis Writing – original draft. **Nina Lazarevic**: Conceptualisation, Methodology, Writing – review and editing. **Anne-Louise Ponsonby**: Conceptualisation, Methodology, Writing – review and editing. **Peter D. Sly**: Conceptualisation, Writing – review and editing. **Aimin Chen**: Conceptualisation, Writing – review and editing. **Tamara L. Blake**: Writing – review and editing. **Jeffrey R. Brook**: Writing – review and editing. **Cassidy Du Berry**: Validation, Writing – review and editing. **Louise King**: Validation, Writing – review and editing. **Dwan Vilcins**: Supervision, Conceptualisation, Methodology, Writing – review and editing.

## Data statement:

The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from childstudy.ca and barwoninfantstudy.org.au

## Funding

TBON was supported by an Australian Government Research Training Program (RTP) Scholarship and a small grant award from the University of Queensland—Child Health Research Centre. PDS is a leadership Fellow (L3) of the National Health and Medical Research Council.

## Declaration of competing interests

The authors declare that they have no competing interests

**Acknowledgements**

We thank the CHILD Cohort Study (CHILD) participant families for their dedication and commitment to advancing health research. CHILD was initially funded by CIHR and AllerGen NCE. Visit CHILD at childstudy.ca. We thank the BIS participants for the generous contribution they have made to this project. We also thank current and past staff for their efforts in recruiting and maintaining the cohort and in obtaining and processing the data and biospecimens. The establishment work and infrastructure for the BIS was provided by the Murdoch Children's Research Institute, Deakin University and Barwon Health. Subsequent funding was secured from the National Health and Medical Research Council of Australia, The Jack Brockhoff Foundation, the Scobie Trust, the Shane O'Brien Memorial Asthma Foundation, the OurWomen's Our Children's Fund Raising Committee Barwon Health, The Shepherd Foundation, the Rotary Club of Geelong, the Ilhan Food Allergy Foundation, GMHBA Ltd, The Gandel Foundation, The Percy Baxter Charitable Trust, Perpetual Trustees and the Gwenyth Raymond Trust. Vanguard Investments Australia Ltd provided funding for analysis of plasticizers in biospecimens. In-kind support was provided by the Cotton On Foundation and CreativeForce. Research at Murdoch Children's Research Institute is supported by the Victorian Government's Operational Infrastructure Support Program.

**REFERENCES**

1.      Foppiano F, Schaub B. Childhood asthma phenotypes and endotypes: a glance into
the mosaic. Molecular and Cellular Pediatrics. 2023;10(1):9.

2.      Kusel MMH, Holt PG, de Klerk N, Sly PD. Support for 2 variants of eczema. Journal
of Allergy and Clinical Immunology. 2005;116(5):1067-72.

3.      Pearce N, Pekkanen J, Beasley R. How much asthma is really attributable to atopy?
Thorax. 1999;54(3):268.

4.      Bølling AK, Sripada K, Becher R, Bekö G. Phthalate exposure and allergic diseases:
Review of epidemiological and experimental evidence. Environment international.
2020;139:105706.

5.      Wang Y, Zhu H, Kannan K. A Review of Biomonitoring of Phthalate Exposures.
Toxics. 2019;7(2):21.

6.      Li M-C, Chen C-H, Guo YL. Phthalate esters and childhood asthma: A systematic
review and congener-specific meta-analysis. Environmental Pollution. 2017;229:655-60.

7.      Xie M-Y, Ni H, Zhao D-S, Wen L-Y, Li K-S, Yang H-H, et al. Exposure to bisphenol A
and the development of asthma: A systematic review of cohort studies. Reproductive
Toxicology. 2016;65:224-9.

8.      Zhang H, Chen S, Chen X, Zhang Y, Han Y, Li J, et al. Exposure to phthalate
increases the risk of eczema in children: Findings from a systematic review and meta-
analysis. Chemosphere. 2023;321:138139.

9.      Soomro Munawar H, Baiz N, Philippat C, Vernet C, Siroux V, Nichole Maesano C, et
al. Prenatal Exposure to Phthalates and the Development of Eczema Phenotypes in Male
Children: Results from the EDEN Mother–Child Cohort Study. Environmental Health
Perspectives. 2018;126(2):027002.

10.     Wang IJ, Chen CY, Bornehag CG. Bisphenol A exposure may increase the risk of
development of atopic disorders in children. International Journal of Hygiene and
Environmental Health. 2016;219(3):311-6.

11.     Lee JY, Lee J, Huh DA, Moon KW. Association between environmental exposure to
phthalates and allergic disorders in Korean children: Korean National Environmental Health
Survey (KoNEHS) 2015–2017. International Journal of Hygiene and Environmental Health.
2021;238.

12.     Boissiere-O'Neill T, Lee WR, Blake TL, Sly PD, Vilcins D. Exposure to endocrine-
disrupting plasticisers and lung function in children and adolescents: A systematic review
and meta-analysis. Environmental research. 2024;243:117751.

13.     Robinson PD, Latzin P, Ramsey KA, Stanojevic S, Aurora P, Davis SD, et al.
Preschool Multiple-Breath Washout Testing. An Official American Thoracic Society
Technical Statement. American Journal of Respiratory and Critical Care Medicine.
2018;197(5):e1-e19.

14.    Vuillermin P, Saffery R, Allen KJ, Carlin JB, Tang ML, Ranganathan S, et al. Cohort
Profile: The Barwon Infant Study. International Journal of Epidemiology. 2015;44(4):1148-60.

15.    Subbarao P, Anand SS, Becker AB, Befus AD, Brauer M, Brook JR, et al. The
Canadian Healthy Infant Longitudinal Development (CHILD) Study: examining
developmental origins of allergy and asthma. Thorax. 2015;70(10):998.

16.    Sugeng EJ, Symeonides C, O'Hely M, Vuillermin P, Sly PD, Vijayasarathy S, et al.
Predictors with regard to ingestion, inhalation and dermal absorption of estimated phthalate
daily intakes in pregnant women: The Barwon infant study. Environment international.
2020;139:105700.

17.    Heffernan AL, Gomez-Ramos MJ, Symeonides C, Hare DJ, Vijayasarathy S,
Thompson K, et al. Harmonizing analytical chemistry and clinical epidemiology for human
biomonitoring studies. A case-study of plastic product chemicals in urine. Chemosphere.
2020;238:124631.

18.    Engel Stephanie M, Villanger Gro D, Nethery Rachel C, Thomsen C, Sakhi Amrit K,
Drover Samantha SM, et al. Prenatal Phthalates, Maternal Thyroid Function, and Risk of
Attention-Deficit Hyperactivity Disorder in the Norwegian Mother and Child Cohort.
Environmental Health Perspectives.126(5):057004.

19.    Hornung RW, Reed LD. Estimation of Average Concentration in the Presence of
Nondetectable Values. Applied Occupational and Environmental Hygiene. 1990;5(1):46-51.

20.    Navaranjan G, Takaro TK, Wheeler AJ, Diamond ML, Shu H, Azad MB, et al. Early
life exposure to phthalates in the Canadian Healthy Infant Longitudinal Development
(CHILD) study: a multi-city birth cohort. Journal of Exposure Science and Environmental
Epidemiology. 2020;30(1):70-85.

21.    Kato K, Silva MJ, Needham LL, Calafat AM. Determination of 16 Phthalate
Metabolites in Urine Using Automated Sample Preparation and On-line
Preconcentration/High-Performance Liquid Chromatography/Tandem Mass Spectrometry.
Analytical Chemistry. 2005;77(9):2985-91.

22.    Heffernan AL, Aylward LL, Toms LML, Eaglesham G, Hobson P, Sly PD, et al. Age-
Related Trends in Urinary Excretion of Bisphenol A in Australian Children and Adults:
Evidence from a Pooled Sample Study Using Samples of Convenience. Journal of
Toxicology and Environmental Health, Part A. 2013;76(18):1039-55.

23.    Gray LEK, Ponsonby A-L, Collier F, O'Hely M, Sly PD, Ranganathan S, et al.
Deserters on the atopic march: Risk factors, immune profile and clinical outcomes of food
sensitized–tolerant infants. Allergy. 2020;75(6):1404-13.

24.    Gray L. Maternal gut bacteria during pregnancy and offspring atopy and wheeze. A
population based cohort study. School of Medicine: Deakin university; 2020.

25.    Australian Bureau of Statistics. 2033.0.55.001 - Census of Population and Housing:
Socio-Economic Indexes for Areas (SEIFA), Australia, 2016 2018 [Available from:
https://www.abs.gov.au/ausstats/abs@.nsf/mf/2033.0.55.001.

26.    Maugeri A, Barchitta M, Agrifoglio O, Favara G, La Mastra C, La Rosa MC, et al. The
impact of social determinants and lifestyles on dietary patterns during pregnancy: evidence
from the "Mamma & Bambino" study. Annali di Igiene : Medicina Preventiva e di Comunita.
2019;31(2 Supple 1):81-9.

27.    Sherriff A, Farrow A, Golding J, Henderson J. Frequent use of chemical household
products is associated with persistent wheezing in pre-school age children. Thorax.
2005;60(1):45.

28.    Harrell FE. General Aspects of Fitting Regression Models. In: Harrell JFE, editor.
Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal
Regression, and Survival Analysis. Cham: Springer International Publishing; 2015. p. 13-44.

29.    Ponsonby A-L. Reflection on modern methods: building causal evidence within high-
dimensional molecular epidemiological studies of moderate size. International Journal of
Epidemiology. 2021;50(3):1016-29.

30.    Ponsonby A-L, Dwyer T, Kemp A, Lim L, Cochrane J, Carmichael A. The use of
mutually exclusive categories for atopic sensitization: A contrasting effect for family size on
house dust mite sensitization compared with ryegrass sensitization. Pediatric Allergy and
Immunology. 2003;14(2):81-90.

31.    Bobb JF, Valeri L, Claus Henn B, Christiani DC, Wright RO, Mazumdar M, et al.
Bayesian kernel machine regression for estimating the health effects of multi-pollutant
mixtures. Biostatistics. 2014;16(3):493-508.

32.    Keil Alexander P, Buckley Jessie P, O'Brien Katie M, Ferguson Kelly K, Zhao S,
White Alexandra J. A Quantile-Based g-Computation Approach to Addressing the Effects of
Exposure Mixtures. Environmental Health Perspectives.128(4):047004.

33.    Wan Y, North ML, Navaranjan G, Ellis AK, Siegel JA, Diamond ML. Indoor exposure
to phthalates and polycyclic aromatic hydrocarbons (PAHs) to Canadian children: the
Kingston allergy birth cohort. Journal of Exposure Science & Environmental Epidemiology.
2022;32(1):69-81.

34.    Hoppin Jane A, Jaramillo R, London Stephanie J, Bertelsen Randi J, Salo Päivi M,
Sandler Dale P, et al. Phthalate Exposure and Allergy in the U.S. Population: Results from
NHANES 2005–2006. Environmental Health Perspectives. 2013;121(10):1129-34.

35.    Granum B, Oftedal B, Agier L, Siroux V, Bird P, Casas M, et al. Multiple
environmental exposures in early-life and allergy-related outcomes in childhood.
Environment international. 2020;144:106038.

36.    Herberth G, Pierzchalski A, Feltens R, Bauer M, Röder S, Olek S, et al. Prenatal
phthalate exposure associates with low regulatory T-cell numbers and atopic dermatitis in
early childhood: Results from the LINA mother-child study. Journal of Allergy and Clinical
Immunology. 2017;139(4):1376-9.e8.

37.    Stelmach I, Majak P, Jerzynska J, Podlecka D, Stelmach W, Polańska K, et al. The
effect of prenatal exposure to phthalates on food allergy and early eczema in inner-city
children. Allergy and asthma proceedings. 2015;36(4):72-8.

38.    Podlecka D, Gromadzińska J, Mikołajewska K, Fijałkowska B, Stelmach I, Jerzynska
J. Longitudinal effect of phthalates exposure on allergic diseases in children. Annals of
Allergy, Asthma & Immunology. 2020;125(1):84-9.

39.    Hill CE, Myers JP, Vandenberg LN. Nonmonotonic Dose–Response Curves Occur in
Dose Ranges That Are Relevant to Regulatory Decision-Making. Dose-Response.
2018;16(3):1559325818798282.

40.    Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, et al. EDC-2: The
Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals.
Endocrine Reviews. 2015;36(6):E1-E150.

41.    Ji H, Wu Z, Chen D, Miao M, Chen H, Shuai W, et al. Individual and joint effects of
phthalates exposure on the risk of early miscarriage. Journal of Exposure Science &
Environmental Epidemiology. 2024;34(4):620-8.

42.    Liew Z, Olsen J, Cui X, Ritz B, Arah OA. Bias from conditioning on live birth in
pregnancy cohorts: an illustration based on neurodevelopment in children after prenatal
exposure to organic pollutants. International Journal of Epidemiology. 2015;44(1):345-54.

43.    Smith LH, VanderWeele TJ. Bounding Bias Due to Selection. Epidemiology.
2019;30(4).

44.    Kuruvilla ME, Lee FE-H, Lee GB. Understanding Asthma Phenotypes, Endotypes,
and Mechanisms of Disease. Clinical Reviews in Allergy & Immunology. 2019;56(2):219-33.

45.    Henderson J, Sherriff A, Farrow A, Ayres JG. Household chemicals, persistent
wheezing and lung function: effect modification by atopy? European Respiratory Journal.
2008;31(3):547.

46.    Baek HS, Won HY, Kim JH, Ha EK, Jee HM, Shin YH, et al. Association of phthalate
exposure and airway dysfunction with mediation by serum periostin. Pediatric Allergy and
Immunology. 2021;32(8):1681-90.

47.    Valle SOR, Kuschnir FC, Solé D, Silva MAV, Silva RI, Da Cunha AJLA. Validity and
Reproducibility of the Asthma Core International Study of Asthma and Allergies in Childhood
(ISAAC) Written Questionnaire Obtained by Telephone Survey. Journal of Asthma.
2012;49(4):390-4.

48.    WILLIAMS HC, JBURNEY PG, PEMBROKE AC, HAY RJ, Party ADDCW. The U.K.
Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation.
British Journal of Dermatology. 1994;131(3):406-16.
709